Tests Normal value Bortezomib- based therapy
Before After
3 courses 6 courses
PT [s] 11.7-13.4 32.5 27.6 18.4
aPTT [s] 28.0-35.0 48 35.9 30.4
aPTT (1+1) ND No correction No correction ND
TT [s] 12.0-17.0 >300 45.5 10.8
FII activity [%of normal value] 50-150% 50.1 ND ND
FV activity [% of normal value] 62-139 16.2 35 48.9
FVIII activity [% of normal value] 50-150 199 ND ND
FX activity [% of normal value] 77-131 75.8 ND ND
Fibrinogen concentration [g/l] 1.8-3.5 4.9 ND ND
vWf: Ag [% of normal value, blood group non-O] 66.1-176.3 140 ND ND
LA1/LA2 [ratio] <1.30 1.01 ND ND
MCF [mm] 50-72 97 ND ND
Serum concentration
Monoclonal IgG (protein M) (g/l)   32.0 20 1.3
Total IgG (g/l)   34.9 24.3 6.1
Total lambda free light chain (mg/l)   0.562 0.262 0.314
Abbreviations: PT: Prothrombin Time; aPTT: Activated Partial Thromboplastin Time; TT: Thrombin Time; (1+1): Equal plasma volume mixing test; FII: Factor II; FV: Factor V; FVIII: Factor VIII; FX: Factor X; vWf:Ag: von Willebrand Factor Antigen; LA: Lupus Anticoagulant; MCF: Maximal Clot Firmness (EXTEM mode); ND: Not Done
Table 1: The results of coagulation system evaluation in patient with recurrent multiple myeloma and retroperitoneal hematoma during treatment with bortezomib - based therapy. Bottom part of the Table shown the results of periodic monitoring of monoclonal protein concentration in the serum.